AI Uncovered Tue, 06 Oct 2026 08:02:15 -0400 https://yseop.com/ en-us © 2026 AI Uncovered yes 542ffea5-7022-55e0-b04d-649f486d3c8c Timothy Martin, Executive VP of Product at Yseop episodic false Buzzsprout (https://www.buzzsprout.com) AI, Technology, Startups, Artificial intelligence, NLG, NLP, ChatGPT, LLM, Timothy Martin, Executive VP of Product at Yseop https://storage.buzzsprout.com/nsmyas8ye0vr4zw3p4egbqf2p9gx?.jpg AI Uncovered https://yseop.com/ Timothy MARTIN Karla Childers - Ethical Guardrails for AI in Pharma Karla Childers - Ethical Guardrails for AI in Pharma We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development.

In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discuss how existing ethical frameworks are being challenged by the rise of generative AI and why maintaining human oversight is critical—especially in high-context areas like clinical trial design, consent and medical communications. Karla also shares her views on the future of data privacy, the complexity of patient agency and how to avoid losing trust in the race for efficiency.

Karla is a strong advocate for using innovation responsibly. From her work with internal bioethics committees to her perspective on evolving regulatory expectations, she offers bold insights into how the industry can modernize without compromising ethics or equity.


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development.

In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discuss how existing ethical frameworks are being challenged by the rise of generative AI and why maintaining human oversight is critical—especially in high-context areas like clinical trial design, consent and medical communications. Karla also shares her views on the future of data privacy, the complexity of patient agency and how to avoid losing trust in the race for efficiency.

Karla is a strong advocate for using innovation responsibly. From her work with internal bioethics committees to her perspective on evolving regulatory expectations, she offers bold insights into how the industry can modernize without compromising ethics or equity.


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Karla Childers, VP Bioethics, Policy & Partnerships at Johnson & Johnson Buzzsprout-17190325 Tue, 03 Jun 2025 14:00:00 +0200 1767 AI, Artificial Intelligence, Generative AI, GenAI, Bioethics, Ethics in Pharma, Patient-Centered Innovation, Life Sciences, Pharmaceutical, PharmaTech, Data Privacy, Consent, Informed Consent, Clinical Trials, Human Oversight, GxP, Responsible AI, Digital 14 full false Oeystein Kjoersvik - Auditing AI: Quality, Compliance & the Role of GenAI in Pharma Oeystein Kjoersvik - Auditing AI: Quality, Compliance & the Role of GenAI in Pharma We’re excited to welcome Oeystein Kjoersvik to AI Uncovered. Oeystein leads the Generative AI program within the Quality Assurance team at Merck, where he focuses on developing AI tools and applying a quality-first approach to ensure safe, effective use of AI in GxP-regulated environments.

In this episode, Tim and Oeystein delve into the challenges of adopting AI in regulated settings, the complexity of validating GenAI tools, and the transition from traditional processes to AI-augmented systems. They also explore Oeystein’s work with the IMPALA Consortium and the importance of cross-industry collaboration to identify and scale high-value use cases for Generative AI.

Before his current role, Oeystein served as a Product Owner in Analytics at Merck IT, building analytics platforms and integrating data science across systems. He also contributed as a Machine Learning Subject Matter Expert to TransCelerate’s Intelligent Automation Group, advancing AI applications in pharmacovigilance.

Oeystein brings a rare blend of technical expertise and regulatory insight. He’s passionate about helping teams adopt AI responsibly and transparently—ensuring innovation aligns with quality across the pharmaceutical landscape.


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We’re excited to welcome Oeystein Kjoersvik to AI Uncovered. Oeystein leads the Generative AI program within the Quality Assurance team at Merck, where he focuses on developing AI tools and applying a quality-first approach to ensure safe, effective use of AI in GxP-regulated environments.

In this episode, Tim and Oeystein delve into the challenges of adopting AI in regulated settings, the complexity of validating GenAI tools, and the transition from traditional processes to AI-augmented systems. They also explore Oeystein’s work with the IMPALA Consortium and the importance of cross-industry collaboration to identify and scale high-value use cases for Generative AI.

Before his current role, Oeystein served as a Product Owner in Analytics at Merck IT, building analytics platforms and integrating data science across systems. He also contributed as a Machine Learning Subject Matter Expert to TransCelerate’s Intelligent Automation Group, advancing AI applications in pharmacovigilance.

Oeystein brings a rare blend of technical expertise and regulatory insight. He’s passionate about helping teams adopt AI responsibly and transparently—ensuring innovation aligns with quality across the pharmaceutical landscape.


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Oeystein Kjoersvik, Technology Auditor & Quality Projects Lead at Merck Buzzsprout-16870577 Mon, 31 Mar 2025 15:00:00 +0200 1971 AI, Artificial Intelligence, Generative AI, GenAI, Pharma, Pharmaceutical, GxP, Compliance, Quality Assurance, Regulatory, Audit, Life Sciences, Regulatory Affairs, AI in Pharma, Pharmacovigilance, PV, Digital Transformation, TransCelerate, AI Governance, 13 full false Emmanuel Walckenaer: AI’s Real-World Impact on Pharma & What’s Next in 2025 Emmanuel Walckenaer: AI’s Real-World Impact on Pharma & What’s Next in 2025 We’re thrilled to welcome  Emmanuel Walckenaer, CEO of Yseop, back to AI Uncovered for a follow-up conversation on the rapid evolution of AI in biopharma. Since his last appearance, the industry has made significant strides in harnessing AI for regulatory submissions, clinical workflows, and medical writing—areas where Yseop is leading the charge in transforming content generation.

In this episode, Tim and Emmanuel revisit the biggest AI breakthroughs of 2024 and explore how the pharmaceutical sector is shifting from skepticism to large-scale adoption. They discuss real-world success stories, the growing impact of federated data sharing, and what companies should prioritize as they plan for 2025 and beyond.

With his unique perspective on SaaS growth, AI regulation, and enterprise adoption, Emmanuel provides invaluable insights for professionals navigating the intersection of AI and life sciences. If you're looking to understand the next wave of AI-driven innovation in pharma, this is an episode you won't want to miss.


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We’re thrilled to welcome  Emmanuel Walckenaer, CEO of Yseop, back to AI Uncovered for a follow-up conversation on the rapid evolution of AI in biopharma. Since his last appearance, the industry has made significant strides in harnessing AI for regulatory submissions, clinical workflows, and medical writing—areas where Yseop is leading the charge in transforming content generation.

In this episode, Tim and Emmanuel revisit the biggest AI breakthroughs of 2024 and explore how the pharmaceutical sector is shifting from skepticism to large-scale adoption. They discuss real-world success stories, the growing impact of federated data sharing, and what companies should prioritize as they plan for 2025 and beyond.

With his unique perspective on SaaS growth, AI regulation, and enterprise adoption, Emmanuel provides invaluable insights for professionals navigating the intersection of AI and life sciences. If you're looking to understand the next wave of AI-driven innovation in pharma, this is an episode you won't want to miss.


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Emmanuel Walckenaer, CEO of Yseop Buzzsprout-16616833 Thu, 20 Feb 2025 11:00:00 +0100 1436 AI, Technology, Startups, Artificial Intelligence, Pharmaceutical, Automation, Pharma, Drug Submission, Generative AI, Gen AI, SaaS, Digital Transformation, Medical Writing, Regulatory Submissions, AI in Pharma, Life Sciences, ROI in AI, AI Adoption, Drug 12 full false Meredith Brown-Tuttle: AI’s Impact on Global Regulatory Strategy and the Future of Pharma Meredith Brown-Tuttle: AI’s Impact on Global Regulatory Strategy and the Future of Pharma We welcome Meredith Brown-Tuttle to AI Uncovered.  Meredith is the Chief Regulatory Strategist at Regulatorium, where she applies her 33 years of experience in the pharmaceutical and biologics industry. She specializes in working with small and medium-sized drug, biologic and combination product companies to navigate global regulatory strategy, intelligence and submission requirements. With a strong focus on innovation, Meredith is dedicated to revolutionizing regulatory science by integrating AI and in silico modeling into every stage of drug development. 

Most recently, Meredith has focused on advancing global regulatory science through the development of AI tools, aiming to streamline submission processes and improve outcomes for the industry. Her vision includes a future where entirely digital INDs, BLAs and NDAs become standard practice, supported by the widespread use of in silico modeling, digital twins and federated data sharing to enable collaboration without compromising proprietary information.

In this episode, Tim  and Meredith explore the evolving landscape of global regulatory strategy and how AI can revolutionize regulatory science. Meredith shares insights from her extensive career, including her experience in crafting INDs and NDAs, her thoughts on transforming data validation standards across the industry and providing strategic guidance to companies navigating complex regulatory requirements. She also delves into the challenges and opportunities presented by AI. 

In addition to her work at Regulatorium, Meredith serves as a board member at the Alliance for Artificial Intelligence in Healthcare (AAIH), showcasing her commitment to leveraging innovation in regulatory affairs. Meredith is also an accomplished author of over 70 articles and two books, and she has trained thousands of professionals on writing INDs and conducting effective regulatory submissions. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Meredith Brown-Tuttle to AI Uncovered.  Meredith is the Chief Regulatory Strategist at Regulatorium, where she applies her 33 years of experience in the pharmaceutical and biologics industry. She specializes in working with small and medium-sized drug, biologic and combination product companies to navigate global regulatory strategy, intelligence and submission requirements. With a strong focus on innovation, Meredith is dedicated to revolutionizing regulatory science by integrating AI and in silico modeling into every stage of drug development. 

Most recently, Meredith has focused on advancing global regulatory science through the development of AI tools, aiming to streamline submission processes and improve outcomes for the industry. Her vision includes a future where entirely digital INDs, BLAs and NDAs become standard practice, supported by the widespread use of in silico modeling, digital twins and federated data sharing to enable collaboration without compromising proprietary information.

In this episode, Tim  and Meredith explore the evolving landscape of global regulatory strategy and how AI can revolutionize regulatory science. Meredith shares insights from her extensive career, including her experience in crafting INDs and NDAs, her thoughts on transforming data validation standards across the industry and providing strategic guidance to companies navigating complex regulatory requirements. She also delves into the challenges and opportunities presented by AI. 

In addition to her work at Regulatorium, Meredith serves as a board member at the Alliance for Artificial Intelligence in Healthcare (AAIH), showcasing her commitment to leveraging innovation in regulatory affairs. Meredith is also an accomplished author of over 70 articles and two books, and she has trained thousands of professionals on writing INDs and conducting effective regulatory submissions. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Meredith Brown-Tuttle, Chief Regulatory Strategist at Regulatorium Buzzsprout-16412839 Mon, 13 Jan 2025 16:00:00 +0100 1726 AI, Technology, Startups, Artificial intelligence, Pharmaceutical, Pharmacology, PK, Biologic, automation, pharma, Drug submission, IND, Gen AI, Generative AI, digital transformation, NDA, AI in Pharma, Regulatory Science, Global Regulatory Strategy, Drug 11 full false Michael Penlington - Impact of AI and New Standards in Clinical Trials Michael Penlington - Impact of AI and New Standards in Clinical Trials We welcome Michael Penlington to AI Uncovered. Michael has been working in Pharma for his entire career including roles in leading development of Vaccines and Clinical reporting at Novartis, as well as Senior Director roles of Science writing, Global Medical Writing and Medical Writing Center of Excellence at GSK.

Most recently, Michael has taken on a new challenge as Director of Digital Clinical Development Solutions at Nurocor.

In this episode, Tim and Michael discuss digital transformation in the pharmaceutical industry, with a particular focus on the role of AI in clinical development. They delve into the current trends, challenges and the driving forces behind this digital revolution in pharma. Michael shares insights from his extensive career, including his experience in medical writing and as a Director of Digital Clinical Development Solutions. He also provides insights on the impact of new standards like ICH M11 on study design, clinical trial management and data management, offering a glimpse into what the future holds for clinical processes. Michael is deeply engaged in the intersection of digital technology and life sciences, making him a leading voice in this transformative era for pharma. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Michael Penlington to AI Uncovered. Michael has been working in Pharma for his entire career including roles in leading development of Vaccines and Clinical reporting at Novartis, as well as Senior Director roles of Science writing, Global Medical Writing and Medical Writing Center of Excellence at GSK.

Most recently, Michael has taken on a new challenge as Director of Digital Clinical Development Solutions at Nurocor.

In this episode, Tim and Michael discuss digital transformation in the pharmaceutical industry, with a particular focus on the role of AI in clinical development. They delve into the current trends, challenges and the driving forces behind this digital revolution in pharma. Michael shares insights from his extensive career, including his experience in medical writing and as a Director of Digital Clinical Development Solutions. He also provides insights on the impact of new standards like ICH M11 on study design, clinical trial management and data management, offering a glimpse into what the future holds for clinical processes. Michael is deeply engaged in the intersection of digital technology and life sciences, making him a leading voice in this transformative era for pharma. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Michael Penlington, Director of Digital Clinical Development Solutions at Nurocor Buzzsprout-15592653 Fri, 16 Aug 2024 18:00:00 +0200 2599 AI, Technology, Startups, Artificial intelligence, ChatGPT, Lifescience, Clinical process, automation, pharma, Clinical trial, ICH, Gen AI, Generative AI, digital transformation, Medical writing, 10 full false Rohit Sood - Digital Transformation & AI's Role in Life Sciences Rohit Sood - Digital Transformation & AI's Role in Life Sciences We welcome Rohit Sood to AI Uncovered. Rohit is a seasoned executive with a strong background in commercialization and technology use in life sciences. He currently advises a variety of life science services and Private Equity firms on operations, growth and digital transformation. With over 25 years of experience in the life sciences and technology industries, Rohit has held multiple leadership roles, leveraging his expertise in AI, cloud computing and digital transformation.

Rohit holds a degree in Computer Science and Applied Mathematics and an MBA from Rutgers. He is currently an adjunct lecturer at Rutgers and is pursuing his DBA in the area of scientific/technological evolution and its impact on oncology commercialization.

In this episode, Tim and Rohit discuss life sciences, digital transformation and the use of generative AI in this industry. They delve into the trends, challenges and success stories of implementing AI in life sciences, exploring how digital transformation drives innovation and efficiency. Rohit provides valuable insights on how startups can differentiate themselves and shares best practices for digital transformation,  highlighting  successful strategies from his extensive consulting experience. Rohit is passionate about the intersection of technology and business and enjoys actively mentoring startups and young professionals. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Rohit Sood to AI Uncovered. Rohit is a seasoned executive with a strong background in commercialization and technology use in life sciences. He currently advises a variety of life science services and Private Equity firms on operations, growth and digital transformation. With over 25 years of experience in the life sciences and technology industries, Rohit has held multiple leadership roles, leveraging his expertise in AI, cloud computing and digital transformation.

Rohit holds a degree in Computer Science and Applied Mathematics and an MBA from Rutgers. He is currently an adjunct lecturer at Rutgers and is pursuing his DBA in the area of scientific/technological evolution and its impact on oncology commercialization.

In this episode, Tim and Rohit discuss life sciences, digital transformation and the use of generative AI in this industry. They delve into the trends, challenges and success stories of implementing AI in life sciences, exploring how digital transformation drives innovation and efficiency. Rohit provides valuable insights on how startups can differentiate themselves and shares best practices for digital transformation,  highlighting  successful strategies from his extensive consulting experience. Rohit is passionate about the intersection of technology and business and enjoys actively mentoring startups and young professionals. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Rohit Sood, Growth Advisor in Life Science Strategy & Operations Buzzsprout-15314812 Tue, 02 Jul 2024 15:00:00 +0200 2694 AI, Technology, Startups, Artificial intelligence, ChatGPT, Lifescience, company, automation, companies, firms, LLMs, Gen AI, Generative AI, enterprise 9 full false Fred Schonenberg - The Vital Role of GenAI in Enterprises Fred Schonenberg - The Vital Role of GenAI in Enterprises We welcome Fred Schonenberg to AI Uncovered. Fred is the founder and CEO of VentureFuel. He has created an innovation framework that bridges the VC, Angel, and Startup ecosystem with enterprises to deliver tangible technology solutions that drive growth. In his role at Venture Fuel, Fred has worked with over 100 companies from General Mills to Netflix.

He is a frequent speaker at industry events such as SXSW, Ad Tech, and Advertising Week and is published in broad media publications including Huffington post, Creator Magazine and Ad Week.

In this episode Tim and Fred discuss generative AI and the role and collaboration between venture capital firms, startups, and enterprises. Fred has worked with over 100 companies, from General Mills to Beam Suntory to Netflix. He has helped companies discover and implement new technologies and delivered breakthrough results including an 18.7% uptick in sales , $10m+ savings, and 5x increase in purchase intent. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Fred Schonenberg to AI Uncovered. Fred is the founder and CEO of VentureFuel. He has created an innovation framework that bridges the VC, Angel, and Startup ecosystem with enterprises to deliver tangible technology solutions that drive growth. In his role at Venture Fuel, Fred has worked with over 100 companies from General Mills to Netflix.

He is a frequent speaker at industry events such as SXSW, Ad Tech, and Advertising Week and is published in broad media publications including Huffington post, Creator Magazine and Ad Week.

In this episode Tim and Fred discuss generative AI and the role and collaboration between venture capital firms, startups, and enterprises. Fred has worked with over 100 companies, from General Mills to Beam Suntory to Netflix. He has helped companies discover and implement new technologies and delivered breakthrough results including an 18.7% uptick in sales , $10m+ savings, and 5x increase in purchase intent. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Fred Schonenberg, Founder and CEO at VentureFuel Buzzsprout-14624105 Mon, 04 Mar 2024 16:00:00 +0100 2242 AI, Technology, Startups, Artificial intelligence, NLG, NLP, ChatGPT, LLM, company, automation, companies, firms, LLMs, Gen AI, Generative AI, enterprise 8 full false Sarah Tilly - AI in Medical Writing Sarah Tilly - AI in Medical Writing Welcome Sarah Tilly to AI Uncovered. Sarah is the Founder and Director of Azur Health Science, a regulatory writing consultancy based in France.

Guided by her expertise as a member of the European Medical Writers Association (EMWA), Tim and Sarah discuss what steps are being taken to better understand the benefits of AI for medical writing. Sarah has been involved in medical writing since 2006 for a variety of companies and is the EMWA president-elect. She mentors and provides training to new medical writers and conducts regular workshops at EMWA conferences. 

Sara holds a degree in Biology, a Postgraduate Certificate in International Health Technology Assessment, Pricing and Reimbursement, and is completing an executive MBA with a focus in Healthcare Management. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Welcome Sarah Tilly to AI Uncovered. Sarah is the Founder and Director of Azur Health Science, a regulatory writing consultancy based in France.

Guided by her expertise as a member of the European Medical Writers Association (EMWA), Tim and Sarah discuss what steps are being taken to better understand the benefits of AI for medical writing. Sarah has been involved in medical writing since 2006 for a variety of companies and is the EMWA president-elect. She mentors and provides training to new medical writers and conducts regular workshops at EMWA conferences. 

Sara holds a degree in Biology, a Postgraduate Certificate in International Health Technology Assessment, Pricing and Reimbursement, and is completing an executive MBA with a focus in Healthcare Management. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Sarah Tilly, Founder & Director of Azur Health Science and EMWA president-elect Buzzsprout-13959840 Mon, 13 Nov 2023 11:00:00 +0100 1914 AI, Technology, Startups, Artificial intelligence, regulatory, NLG, NLP, ChatGPT, LLM, CSR, EMWA, life sciences, automation, pharma, biopharma, medical writing, medical writer, clinical trials, regulatory affairs 7 full false Derek Kerton - AI’s Impact on Automobiles Derek Kerton - AI’s Impact on Automobiles We welcome Derek Kerton to AI Uncovered. Derek is the Founder and Chairman of the Autotech Council in Silicon Valley. His work brings global car companies together with startups to drive discussion around new technologies and their possible impact on the car industry.

In this episode, Derek shares his expertise with Tim, offering valuable insights into the ever-evolving landscape of automotive tech. They discuss how cars are becoming safer and more efficient using innovation. They delve into groundbreaking breakthroughs across the automotive industry over the last decade, like connected cars, autonomous driving, and the impact of the sharing economy. They then look at what how AI is affecting the car experience, and what the future might hold.

Along with his work, Derek has authored over 800 articles for news outlets including Techdirt, RCR Wireless, and GigaOm. He is also the co-author of the book Going Mobile: Building the real time enterprise with mobile applications. Derek has an MBA from Cornell University and an Economics degree from the University of Waterloo. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Derek Kerton to AI Uncovered. Derek is the Founder and Chairman of the Autotech Council in Silicon Valley. His work brings global car companies together with startups to drive discussion around new technologies and their possible impact on the car industry.

In this episode, Derek shares his expertise with Tim, offering valuable insights into the ever-evolving landscape of automotive tech. They discuss how cars are becoming safer and more efficient using innovation. They delve into groundbreaking breakthroughs across the automotive industry over the last decade, like connected cars, autonomous driving, and the impact of the sharing economy. They then look at what how AI is affecting the car experience, and what the future might hold.

Along with his work, Derek has authored over 800 articles for news outlets including Techdirt, RCR Wireless, and GigaOm. He is also the co-author of the book Going Mobile: Building the real time enterprise with mobile applications. Derek has an MBA from Cornell University and an Economics degree from the University of Waterloo. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Derek Kerton, Founder & Chairman of the Autotech Council in Silicon Valley Buzzsprout-13510276 Mon, 04 Sep 2023 16:00:00 +0200 2637 AI, Autotech, Artificial intelligence, NLG, NLP, ChatGPT, LLM, automobile, automation, chatbot, bot, LLMs, auto, vehicule, tesla, elon musk, technology, auto tech, auto technology, startups, automotive, cars, 6 full false Daniel O'Mahony - BioPharma 4.0 & The Role of AI in Drug Manufacturing Daniel O'Mahony - BioPharma 4.0 & The Role of AI in Drug Manufacturing We welcome Daniel O'Mahony to AI Uncovered. Daniel is a senior manager of sales and business consulting with Körber Pharma, a pharma manufacturing software company. Along with his work at Körber, Dan lectures with the national institute of bioprocessing research and training and at the Atlantic Technical University covering topics like BioPharma 4.0 and digital transformation.

In this episode, Tim and Dan look at the impact of AI on the pharmaceutical manufacturing processes and the delicate balance between digital transformation, risk, and productivity gains in life sciences. They discuss why Ireland has been a hub for manufacturing and pharmaceutical growth over the last 60 years. Next, they dig into the digital transformation happening in drug manufacturing, the role of AI on the process, and the future of personalized drugs. 

Dan has a masters degrees in bioprocessing from Atlantic Technical University and in Pharmaceutical business and technology from Griffith College. He is based in Dublin, Ireland. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Daniel O'Mahony to AI Uncovered. Daniel is a senior manager of sales and business consulting with Körber Pharma, a pharma manufacturing software company. Along with his work at Körber, Dan lectures with the national institute of bioprocessing research and training and at the Atlantic Technical University covering topics like BioPharma 4.0 and digital transformation.

In this episode, Tim and Dan look at the impact of AI on the pharmaceutical manufacturing processes and the delicate balance between digital transformation, risk, and productivity gains in life sciences. They discuss why Ireland has been a hub for manufacturing and pharmaceutical growth over the last 60 years. Next, they dig into the digital transformation happening in drug manufacturing, the role of AI on the process, and the future of personalized drugs. 

Dan has a masters degrees in bioprocessing from Atlantic Technical University and in Pharmaceutical business and technology from Griffith College. He is based in Dublin, Ireland. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Daniel O' Mahony, Sr. Manager of Sales and Business Consulting with Körber Pharma Buzzsprout-13263518 Fri, 21 Jul 2023 18:00:00 +0200 1797 AI, Technology, Startups, Artificial intelligence, NLG, NLP, ChatGPT, LLM, life sciences, automation, manufacture, medicine, LLMs, pharma, pharmaceutical, manufacturing, biopharma, Dalle 5 full false Gregor Mittersinker - "AI, ChatGPT, and the Impact on UX & Design" Gregor Mittersinker - "AI, ChatGPT, and the Impact on UX & Design" We welcome Gregor Mittersinker to AI Uncovered. Gregor is the founder and creative director at Loft. Loft focuses on product development and design with a specialty in building large product ecosystems. 

In this episode, Tim and Gregor dive deep into UX and design. They discuss how LLMs, like ChatGPT, have impacted UI design, specifically around conversational UI and prompt interfaces. They evaluate how industry specific applications might use a variety of UI techniques to deal with the nuances of AI in the future.

Gregor brings over 30 years of experience to product development and design. He holds over 100 patents and has worked with brands such as Bose, 3M, Dell, Square and Segate. Gregor has a BA and MA from the Technical University Vienna and University of Applied arts in Vienna. Gregor is currently an adjunct professor at the RISD (Rhode Island School of Design).


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Gregor Mittersinker to AI Uncovered. Gregor is the founder and creative director at Loft. Loft focuses on product development and design with a specialty in building large product ecosystems. 

In this episode, Tim and Gregor dive deep into UX and design. They discuss how LLMs, like ChatGPT, have impacted UI design, specifically around conversational UI and prompt interfaces. They evaluate how industry specific applications might use a variety of UI techniques to deal with the nuances of AI in the future.

Gregor brings over 30 years of experience to product development and design. He holds over 100 patents and has worked with brands such as Bose, 3M, Dell, Square and Segate. Gregor has a BA and MA from the Technical University Vienna and University of Applied arts in Vienna. Gregor is currently an adjunct professor at the RISD (Rhode Island School of Design).


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> TIMOTHY MARTIN, EXECUTIVE VP OF PRODUCT AT YSEOP / GREGOR MITTERSINKER, FOUNDER AND CREATIVE DIRECTOR AT LOFT Buzzsprout-13022283 Mon, 12 Jun 2023 12:00:00 +0200 2667 AI, Technology, Startups, Artificial intelligence, NLG, NLP, ChatGPT, LLM, life sciences, automation, UX, Design, LLMs, UI, UI Design, Data Science 4 full false Marjo Gazak - "What used to take 8 hours, I can now generate a first draft in 1 second" Marjo Gazak - "What used to take 8 hours, I can now generate a first draft in 1 second" We welcome Marjo Gazak to AI Uncovered. Marjo is a life sciences expert with over 22 years of experience in drug development, regulatory submissions, document development innovation and data mining systems. Tim and Marjo discuss a wide range of topics, from the emergence of automation in the drug delivery process to the future role of generative AI in helping this regulated industry get drugs to market faster.  

Marjo has worked at Eli Lilly and more recently at FibroGen, where she is the Senior Director in Regulatory Affairs and Medical Writing. She has BS and MS degrees in Zoology from Clemson University and a PHD in Aquatic Toxicology from Louisville. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> We welcome Marjo Gazak to AI Uncovered. Marjo is a life sciences expert with over 22 years of experience in drug development, regulatory submissions, document development innovation and data mining systems. Tim and Marjo discuss a wide range of topics, from the emergence of automation in the drug delivery process to the future role of generative AI in helping this regulated industry get drugs to market faster.  

Marjo has worked at Eli Lilly and more recently at FibroGen, where she is the Senior Director in Regulatory Affairs and Medical Writing. She has BS and MS degrees in Zoology from Clemson University and a PHD in Aquatic Toxicology from Louisville. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> Timothy Martin, Executive VP of Product at Yseop / Marjo Gazak, Sr. Director in Regulatory Affairs and Medical Writing at FibroGen Buzzsprout-12776456 Wed, 03 May 2023 16:00:00 +0200 2830 AI, Technology, Startups, Artificial intelligence, NLG, NLP, ChatGPT, LLM, life sciences, automation 3 full false Emmanuel Walckenaer - "In the next five years, 80% of the life sciences industry will be using this type of AI" Emmanuel Walckenaer - "In the next five years, 80% of the life sciences industry will be using this type of AI" The second episode features a conversation with Emmanuel Walckenaer, CEO of Yseop. Yseop is reimagining the future of scientific writing through generative AI. The company's mission is to get medicine into the hands of those who need it, faster.

Tim and Emmanuel shares insights on the state of natural language generation (NLG) today and the roots of the technology. They discuss how generative AI is automating parts of the clinical document landscape and why the tech is helping scientific writers be more productive. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> The second episode features a conversation with Emmanuel Walckenaer, CEO of Yseop. Yseop is reimagining the future of scientific writing through generative AI. The company's mission is to get medicine into the hands of those who need it, faster.

Tim and Emmanuel shares insights on the state of natural language generation (NLG) today and the roots of the technology. They discuss how generative AI is automating parts of the clinical document landscape and why the tech is helping scientific writers be more productive. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> https://yseop.com/ Timothy Martin, Executive VP of Product at Yseop / Emmanuel Walckenaer, CEO of Yseop Buzzsprout-12578549 Mon, 03 Apr 2023 19:00:00 +0200 1741 AI, Technology, Startups, Artificial intelligence, NLG, NLP, ChatGPT, LLM, 2 full false Craig Vachon - “I still think ChatGPT is kind of a gimmick” Craig Vachon - “I still think ChatGPT is kind of a gimmick” The first episode features a conversation with Craig Vachon, CEO of AI Redefined (AIR) and Head of US Operations at NextStage AM. Craig is an angel investor, author, TED speaker, and chairman of Yseop. 

Tim and Craig discuss the AI landscape as it exists today and then go into the benefits and limitations of ChatGPT and LLMs, especially for more regulated industries. They touch on some of the challenges involved with AI startups, advice for entrepreneurs, and practical considerations of rolling out AI technology to customers. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> The first episode features a conversation with Craig Vachon, CEO of AI Redefined (AIR) and Head of US Operations at NextStage AM. Craig is an angel investor, author, TED speaker, and chairman of Yseop. 

Tim and Craig discuss the AI landscape as it exists today and then go into the benefits and limitations of ChatGPT and LLMs, especially for more regulated industries. They touch on some of the challenges involved with AI startups, advice for entrepreneurs, and practical considerations of rolling out AI technology to customers. 


Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> https://yseop.com/blog/ai-uncovered-episode-one-generative-ai-chatgpt/ Timothy Martin, Executive VP of Product at Yseop / Craig Vachon, AI-Redefined CEO & Head of US Operations at NextStage AM Buzzsprout-12319241 Wed, 01 Mar 2023 16:00:00 +0100 1593 AI, Technology, Startups, Artificial intelligence, NLG, NLP, ChatGPT, LLM, 1 full false Welcome to AI Uncovered! Welcome to AI Uncovered!
Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]>
Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. 

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product. 

]]> https://yseop.com/ Yseop Buzzsprout-12344711 Tue, 28 Feb 2023 14:00:00 +0100 44 AI, Technology, Startups, Artificial intelligence, NLG, NLP, ChatGPT, LLM, 0 full false